China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BGM0504, a dual agonist targeting GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulin-stimulating polypeptide). The targeted indications for BGM0504 are weight loss and type 2 diabetes.
Development and Targeted Indications
BGM0504 is under development to control blood sugar, reduce weight, and treat nonalcoholic steatohepatitis (NASH). Currently, there is no similar product approved for marketing in China. This positions BGM0504 as a potentially innovative therapy in the treatment landscape for metabolic disorders.
Global Landscape and Comparative Analysis
In comparison, US-based major Eli Lilly’s GIP/GLP-1 agonist tirzepatide has been approved to control blood sugar in type 2 diabetes in the US, Europe, and Japan. Eli Lilly is also conducting a clinical study for weight loss indications. The approval of BGM0504 for clinical trials by the NMPA marks a significant step forward for BrightGene in developing a novel dual agonist to address significant unmet medical needs in weight management and diabetes treatment.-Fineline Info & Tech
